Published in Lab Business Week, October 7th, 2007
Under the terms of the agreement, Forest will initially pay Microbia $70 million in licensing fees. Microbia and Forest will jointly and equally fund development and commercialization of linaclotide in the United States, sharing profits equally. Additionally, Forest will have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week